Novavax COVID-19 vaccine is 89.3 percent effective, but less so against variants, shows UK trial

Novavax Inc. said Thursday that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new mutated versions of the virus circulating in that country and South Africa.

The announcement comes amid worry about whether a variety of vaccines being rolled out around the world will be strong enough to protect against worrisome new variants – and as the world desperately needs new types of shots to boost scarce supplies.

The study of 15,000 people in Britain is still underway. But an interim analysis found 62 participants so far have been diagnosed with COVID-19 – only six of them in the group that got vaccine and the rest who received dummy shots.

The infections occurred at a time when Britain was experiencing a jump in COVID-19 caused by a more contagious variant. A preliminary analysis found over half of the trial participants who became infected had the mutated version. The numbers are very small, but Novavax said they suggest the vaccine is nearly 96% effective against the older coronavirus and nearly 86% effective against the new variant. The findings are based on cases that occurred at least a week after the second dose.

“Both those numbers are dramatic demonstrations of the ability of our vaccine to develop a very potent immune response,” Novavax CEO Stanley Erck said in a call with investors late Thursday.

Scientists have been even more worried about a variant first discovered in South Africa that carries different mutations. Results from a smaller Novavax study in that country suggests the vaccine does work but not nearly as well as it does against the variant from Britain.

Dr Sonia Macieiewski (R) and Dr Nita Patel, Director of Antibody discovery and Vaccine development, look at a sample of respiratory virus at Novavax labs in Maryland on 20 March, one of the labs developing a vaccine for COVID-19. AFP

The South African study included some volunteers with HIV. Among the HIV-negative volunteers, the vaccine appears 60% effective. Including volunteers with HIV, overall the protection was 49%, the company said. While genetic testing still is underway, so far about 90% of the COVID-19 illnesses found in the South African study appear due to the new mutant.

“These are good results. There is reason to be optimistic” about the 60% effectiveness, said Glenda Gray, head of the South African Medical Research Council. Even against the new variant that now causes more than 90% of new cases in that country, “we’re still seeing vaccine efficacy,” she said.

More concerning is what the study showed about a totally different question — the chances of people getting COVID-19 a second time, said the leader of the South African study, Shabir Madhi of the University of the Witwatersrand in Johannesburg. Tests suggested that nearly a third of study participants had been previously infected, yet rates of new infections in the placebo group were similar.

“Past infection with early variants of the virus in South Africa does not protect” against infection with the new one, he said. “There doesn’t seem to be any protection derived.”

Novavax said it needs some additional data before it can seek British authorization for the vaccine’s use, sometime in the next month or so. A larger study in the U.S. and Mexico has enrolled slightly over half of the needed 30,000 volunteers. Novavax said it’s not clear if the Food and Drug Administration will need data from that study, too, before deciding whether to allow U.S. use.

Meanwhile, it is starting to develop a version of the vaccine that could more specifically target the mutations found in South Africa, in case health authorities eventually decide that updated dosing is needed.

Vaccines against COVID-19 train the body to recognize the new coronavirus, mostly the spike protein that coats it. But the Novavax candidate is made differently than the first shots being used. Called a recombinant protein vaccine, the Maryland company uses genetic engineering to grow harmless copies of the coronavirus spike protein in insect cells. Scientists extract and purify the protein and then mix in an immune-boosting chemical.



from Firstpost Tech Latest News https://ift.tt/3oqWqht

Comments

Post a Comment

Popular posts from this blog

COVID-19 origins: Should we pay more attention to the lab leak theory and formally investigate it?

Image
A year and a half into the pandemic, we still do not know exactly where the SARS-CoV-2 virus, which causes Covid-19, came from. The prevailing view so far has been that the virus “spilled over” from bats into humans. But there are increasing calls to investigate the possibility that it emerged from a lab in Wuhan, China, where Covid first appeared at the end of 2019. So what do we know for sure, and what do we need still to find out? We know the sequence of the SARS-CoV-2 virus is close to that of bat coronaviruses . Several decades ago its “ancestor” was circulating in bat populations in southern Asia. But there are still many unanswered questions: we don’t know how the virus arrived in Wuhan, how its sequence evolved to allow human infection, and under what conditions it infected the first people who crossed its path. And for each of these stages, we don’t know whether there was a human contribution (direct or indirect). Zoonotic transmission pathways, in other words the pas
Read more

Menstrual cups are cheaper, more sustainable than pads and tampons for women

Image
Every year in America, women spend at least US$2.8 billion on sanitary pads and tampons that can take hundreds of years to decompose . Is there a more economical and environmentally friendly way? To find out, we asked Susan Powers , a professor of sustainable environmental systems at Clarkson University about her work comparing the environmental impact of tampons, sanitary pads and menstrual cups. What is a menstrual cup? A menstrual cup is a type of reusable feminine hygiene product. It’s a small, flexible bell-shaped cup made of rubber or silicone that a woman inserts into her vagina to catch and collect menstrual fluid. It can be used for up to 12 hours, after which it is removed to dispose of the fluid and cleaned. The cup is rinsed with hot water and soap between each insertion and sterilized in boiling water at least once per period. A cup can last up to 10 years . Although menstrual cups have been around for decades, they historically have been less popular than pads or ta
Read more

Human bodies respond to infections differently depending on the time of day

Image
When microorganisms – such as bacteria or viruses – infect us, our immune system jumps into action. It’s highly trained to sense and eliminate infections and clear up any damage caused by them. It’s typically assumed our immune systems work the exact same way regardless of whether an infection occurs during the day or at night. But research spanning over half a century now shows our bodies actually respond differently at day and night. The reason for this is our body clock, and the fact that each cell in the body, including our immune cells, can tell what time of day it is. Our body clock has evolved over millions of years to help us survive. Every cell in the body has a collection of proteins that indicate the time depending on their levels. Knowing whether it’s day or night means our body can adjust its functions and behaviours (such as when we want to eat) to the correct time. Our body clock does this by generating 24 hour rhythms (also termed circadian rhythms ) in how cells f
Read more